Skip to main content
. 2019 Apr 15;10(20):5197–5210. doi: 10.1039/c8sc05542d

Table 2. Antiproliferative activity of novel folate–Ratjadone conjugates against KB-3.1 cancer cells.

Folate–ratjadone conjugate IC50 [nM]
FA-1-Val-Cit-pABA-16R-aminoratjadone 169
FA-2-Val-Cit-pABA-16R-aminoratjadone 336
FA-3-Val-Cit-pABA-16R-aminoratjadone 210
FA-4-(Val-Cit-pABA-16R-aminoratjadone)2 148
FA-5-Val-Cit-pABA-16R-aminoratjadone 237
FA-6-Val-Cit-pABA-16R-aminoratjadone 223
FA-7-Val-Cit-pABA-16R-aminoratjadone 34.3
FA-8-Val-Cit-pABA-16R-aminoratjadone 39.9
FA-9-Val-Cit-pABA-16R-aminoratjadone 50.9
FA-10-Val-Cit-pABA-16R-aminoratjadone 35.3
FA-11-(Val-Cit-pABA-16R-aminoratjadone)3 45.0
FA-3-l-16R-aminoratjadone 29.8
FA-3-l-19-aminoratjadone 48.3
FA-3b-l-16R-aminoratjadone 94.0
FA-5-l-16R-aminoratjadone 50.3
FA-6-l-16R-aminoratjadone 150
FA-7-l-16R-aminoratjadone 190
FA-8-l-16R-aminoratjadone 129
FA-9-l-16R-aminoratjadone 47.6
FA-10-l-16R-aminoratjadone 708
FA-SS-16R-aminoratjadone 295